Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 650

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 650
---
 forma condensed combined financial information. The unaudited pro forma condensed combined financial information, including the notes thereto, are qualified in their entirety by reference to, and should be read in conjunction with, the separate historical audited and unaudited financial statements of Legacy TuHURA, Kintara, and Kineta, as filed with the SEC and included elsewhere in this joint proxy statement/prospectus.422
NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X.The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Transactions and has been prepared for informational purposes only. The Company includes additional financing transactions and transaction accounting adjustments in the unaudited pro forma condensed combined balance sheet as if they had occurred as of September 30, 2024 and in the unaudited pro forma condensed combined statements of operations as if they had occurred as of the earliest period presented, January 1, 2023. The pro forma basic and diluted loss per share amounts presented in the unaudited pro forma condensed combined statements of operations are based upon the number of shares of TuHURA Common Stock outstanding following the reverse share split of 1-35as effected on October 18, 2024 for the Reverse Capitalization, and assuming the share issuances expected in connection with the Mergers occurred on January 1, 2023. Estimated Purchase Price Consideration for the Mergers Estimated purchase price of approximately $30,526 related to the Mergers is comprised of the following components (in thousands):

| Cash Consideration       |     | $ | 10,526 |
| Share Consideration      |     |   | 20,000 |
| Contingent Consideration |     |   |      — |
| Total consideration      |     | $ | 30,526 |

The cash component of the aggregate Merger Consideration in the Mergers will be an estimated cash consideration amount of $10,526 (consisting of a base cash consideration value of $15,000, as stated in the Merger Agreement, less the sum of Kineta’s working capital deficit, if any at the Closing of the Mergers, which is currently estimated to be $4,474 based on the historical financial information of Kineta as of September 30, 2024). Of the estimated cash consideration amount